Deerfield Management Company, L.P.. (series C) 13F annual report
Deerfield Management Company, L.P.. (series C) is an investment fund managing more than $3.09 trillion ran by Flynn Flynn. There are currently 66 companies in Mr. Flynn’s portfolio. The largest investments include Nuvalent Inc and Viatris, together worth $1.11 trillion.
$3.09 trillion Assets Under Management (AUM)
As of 7th November 2023, Deerfield Management Company, L.P.. (series C)’s top holding is 19,991,024 shares of Nuvalent Inc currently worth over $919 billion and making up 29.8% of the portfolio value.
In addition, the fund holds 19,863,485 shares of Viatris worth $196 billion, whose value fell approximately 0.1% in the past six months.
The third-largest holding is Centene worth $137 billion and the next is Neurocrine Biosciences worth $136 billion, with 1,209,714 shares owned.
Currently, Deerfield Management Company, L.P.. (series C)'s portfolio is worth at least $3.09 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Deerfield Management Company, L.P.. (series C)
The Deerfield Management Company, L.P.. (series C) office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Flynn Flynn serves as the Managing Member at Deerfield Management Company, L.P.. (series C).
Recent trades
In the most recent 13F filing, Deerfield Management Company, L.P.. (series C) revealed that it had opened a new position in
Owens & Minor and bought 6,435,000 shares worth $104 billion.
This means they effectively own approximately 0.1% of the company.
Owens & Minor makes up
7.5%
of the fund's Health Care sector allocation and has decreased its share price by 14.1% in the past year.
The investment fund also strengthened its position in Nuvalent Inc by buying
650,000 additional shares.
This makes their stake in Nuvalent Inc total 19,991,024 shares worth $919 billion.
On the other hand, there are companies that Deerfield Management Company, L.P.. (series C) is getting rid of from its portfolio.
Deerfield Management Company, L.P.. (series C) closed its position in Sarepta Therapeutics Inc on 14th November 2023.
It sold the previously owned 88,657,000 shares for $112 million.
Flynn Flynn also disclosed a decreased stake in Viatris by approximately 0.1%.
This leaves the value of the investment at $196 billion and 19,863,485 shares.
One of the largest hedge funds
The two most similar investment funds to Deerfield Management Company, L.P.. (series C) are Sumitomo Mitsui Financial Group, Inc and Millburn Ridgefield Corp. They manage $3.09 trillion and $3.08 trillion respectively.
Flynn Flynn investment strategy
Deerfield Management Company, L.P.. (series C)’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 44.7% of
the total portfolio value.
The fund focuses on investments in the United States as
45.5% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
8% of the total holdings value.
On the other hand, large-cap stocks make up only 6.1% of the portfolio.
The average market cap of the portfolio companies is close to $3.72 billion.
The complete list of Deerfield Management Company, L.P.. (series C) trades based on 13F SEC filings
These positions were updated on November 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Nuvalent Inc |
3.36%
19,991,024
|
$918,987,373,000 | 29.77% |
| Viatris Inc. |
3.92%
19,863,485
|
$195,853,962,000 | 6.34% |
| Centene Corp. |
243.81%
1,990,000
|
$137,071,200,000 | 4.44% |
| Neurocrine Biosciences, Inc. |
39.90%
1,209,714
|
$136,092,825,000 | 4.41% |
| AdaptHealth Corp. |
22.04%
13,607,940
|
$123,832,254,000 | 4.01% |
| Owens & Minor, Inc. |
Opened
6,435,000
|
$103,989,600,000 | 3.37% |
| Catalyst Pharmaceuticals Inc |
Opened
8,192,000
|
$95,764,480,000 | 3.10% |
| Merus N.V |
95.22%
3,876,938
|
$91,418,198,000 | 2.96% |
| Deciphera Pharmaceuticals In |
10.34%
6,897,606
|
$87,737,548,000 | 2.84% |
| Larimar Therapeutics, Inc. |
190.58%
16,941,357
|
$66,918,360,000 | 2.17% |
| Bio Rad Labs Inc |
Opened
173,947
|
$62,351,302,000 | 2.02% |
| IDEAYA Biosciences, Inc. |
Opened
2,268,628
|
$61,207,583,000 | 1.98% |
| Enhabit, Inc. |
Opened
4,997,746
|
$56,224,643,000 | 1.82% |
| Hillevax Inc |
52.95%
4,004,231
|
$53,856,907,000 | 1.74% |
| Brookdale Sr Living Inc |
47.57%
12,679,651
|
$52,493,755,000 | 1.70% |
| Revolution Medicines Inc |
96.45%
1,751,496
|
$48,481,409,000 | 1.57% |
| Integra Lifesciences Hldgs C |
Opened
1,126,827
|
$43,033,523,000 | 1.39% |
| Surgery Partners Inc |
Opened
1,460,000
|
$42,705,000,000 | 1.38% |
| Ars Pharmaceuticals Inc |
Opened
11,077,927
|
$41,874,564,000 | 1.36% |
| Kura Oncology Inc |
66.50%
4,374,044
|
$39,891,281,000 | 1.29% |
| Guardant Health Inc |
Opened
1,329,935
|
$39,419,273,000 | 1.28% |
| Intercept Pharmaceuticals In |
Opened
2,077,893
|
$38,524,136,000 | 1.25% |
| SpringWorks Therapeutics, Inc. |
Opened
1,579,574
|
$36,519,751,000 | 1.18% |
| Cabaletta Bio Inc |
404.06%
2,340,118
|
$35,616,596,000 | 1.15% |
| Caremax Inc |
0.08%
15,873,213
|
$33,651,212,000 | 1.09% |
| Structure Therapeutics Inc |
Opened
627,813
|
$31,654,331,000 | 1.03% |
| Rayzebio Inc |
Opened
1,159,126
|
$25,732,597,000 | 0.83% |
| Docgo Inc |
Opened
4,764,000
|
$25,392,120,000 | 0.82% |
| Biocryst Pharmaceuticals Inc. |
Opened
3,286,000
|
$23,264,880,000 | 0.75% |
| Edgewise Therapeutics Inc |
No change
3,933,137
|
$22,536,875,000 | 0.73% |
| Insulet Corporation |
Opened
127,000
|
$20,255,230,000 | 0.66% |
| Disc Medicine Inc |
Opened
430,000
|
$20,201,400,000 | 0.65% |
| Alignment Healthcare Inc |
Opened
2,747,015
|
$19,064,284,000 | 0.62% |
| Roivant Sciences Ltd |
Opened
1,604,487
|
$18,740,408,000 | 0.61% |
| Caribou Biosciences Inc |
Opened
3,500,000
|
$16,730,000,000 | 0.54% |
| Castle Biosciences, Inc. |
Opened
946,620
|
$15,988,412,000 | 0.52% |
| Day One Biopharmaceuticals I |
63.84%
1,269,992
|
$15,582,802,000 | 0.50% |
| Viking Therapeutics Inc |
Opened
1,279,000
|
$14,158,530,000 | 0.46% |
| Tarsus Pharmaceuticals, Inc. |
43.06%
754,042
|
$13,399,326,000 | 0.43% |
| Verastem Inc |
Opened
1,538,461
|
$12,507,688,000 | 0.41% |
| Denali Therapeutics Inc |
Opened
594,989
|
$12,274,623,000 | 0.40% |
| QuidelOrtho Corporation |
Opened
150,000
|
$10,956,000,000 | 0.35% |
| Cogent Biosciences, Inc. |
81.46%
1,089,345
|
$10,621,114,000 | 0.34% |
| Pulmonx Corp |
70.63%
1,017,958
|
$10,515,506,000 | 0.34% |
| Revance Therapeutics Inc |
Opened
870,000
|
$9,978,900,000 | 0.32% |
| Vigil Neuroscience Inc |
Opened
1,827,400
|
$9,849,686,000 | 0.32% |
| Bicycle Therapeutics plc |
Opened
448,753
|
$9,015,448,000 | 0.29% |
| Tango Therapeutics Inc |
Opened
793,729
|
$8,937,389,000 | 0.29% |
| Prime Medicine Inc |
Opened
885,314
|
$8,445,896,000 | 0.27% |
| 4d Molecular Therapeutics In |
Opened
650,000
|
$8,274,500,000 | 0.27% |
| iTeos Therapeutics, Inc. |
Opened
723,000
|
$7,916,850,000 | 0.26% |
| Fusion Pharmaceuticals Inc. |
Opened
2,823,000
|
$7,339,800,000 | 0.24% |
| Alector, Inc. |
No change
1,055,192
|
$6,837,644,000 | 0.22% |
| The Oncology Institute Inc |
0.68%
3,360,052
|
$4,704,073,000 | 0.15% |
| Genedx Holdings Corp |
Opened
1,253,895
|
$4,564,178,000 | 0.15% |
| Foghorn Therapeutics Inc. |
No change
777,525
|
$3,887,625,000 | 0.13% |
| Nyxoah S A |
12.08%
400,256
|
$2,821,805,000 | 0.09% |
| Black Diamond Therapeutics I |
Opened
930,447
|
$2,670,383,000 | 0.09% |
| Orchard Therapeutics plc |
Opened
316,169
|
$2,443,986,000 | 0.08% |
| Singular Genomics Systems In |
21.33%
4,984,871
|
$1,899,236,000 | 0.06% |
| Acutus Med Inc |
0.47%
2,660,808
|
$1,853,519,000 | 0.06% |
| Annexon Inc |
No change
583,913
|
$1,378,035,000 | 0.04% |
| Cutera Inc |
Opened
154,406
|
$929,524,000 | 0.03% |
| Sarepta Therapeutics Inc |
Closed
88,657,000
|
$111,766,000 | |
| Medavail Holdings Inc |
Opened
16,732
|
$100,392,000 | 0.00% |
| Silk Rd Med Inc |
Closed
2,676,891
|
$97,412,000 | |
| Gilead Sciences, Inc. |
Closed
1,552,639
|
$95,969,000 | |
| Immunogen, Inc. |
Closed
15,020,490
|
$67,592,000 | |
| Mirum Pharmaceuticals Inc |
Closed
3,244,434
|
$63,137,000 | |
| IVERIC bio Inc |
Closed
5,214,000
|
$50,159,000 | |
| Glaukos Corporation |
Closed
1,039,514
|
$47,215,000 | |
| Molina Healthcare Inc |
Closed
167,000
|
$46,695,000 | |
| Cytokinetics Inc |
Closed
1,160,315
|
$45,589,000 | |
| Evolus Inc |
Closed
3,632,751
|
$42,140,000 | |
| Aerie Pharmaceuticals Inc |
Closed
4,695,020
|
$35,213,000 | |
| Sientra Inc |
Opened
10,000
|
$27,800,000 | 0.00% |
| Pharvaris N V |
Closed
1,190,343
|
$26,307,000 | |
| Horizon Therapeutics Pub L |
Closed
313,000
|
$24,965,000 | |
| Sema4 Holdings Corp |
Closed
18,848,488
|
$23,749,000 | |
| Bellus Health Inc |
Closed
2,473,000
|
$22,851,000 | |
| Organogenesis Holdings Inc. |
Closed
4,447,740
|
$21,705,000 | |
| Phreesia Inc |
Closed
857,115
|
$21,436,000 | |
| Syndax Pharmaceuticals Inc |
Closed
1,111,111
|
$21,378,000 | |
| Amedisys Inc. |
Closed
199,000
|
$20,919,000 | |
| Insmed Inc |
Closed
960,484
|
$18,941,000 | |
| Pacira BioSciences Inc |
Closed
292,000
|
$17,024,000 | |
| Alphatec Holdings Inc |
Closed
2,420,547
|
$15,830,000 | |
| AnaptysBio Inc |
Closed
772,000
|
$15,672,000 | |
| Da32 Life Scnce Tec Acqstn C |
Closed
1,600,000
|
$15,504,000 | |
| Inozyme Pharma, Inc. |
Closed
2,696,372
|
$12,862,000 | |
| Profound Med Corp |
Closed
1,713,797
|
$12,494,000 | |
| Kezar Life Sciences Inc |
Closed
1,419,000
|
$11,735,000 | |
| TG Therapeutics Inc |
Closed
2,677,500
|
$11,379,000 | |
| Eucrates Biomedical Acqu Cor |
Closed
999,999
|
$9,900,000 | |
| Sarissa Capital Acquisitn Co |
Closed
999,999
|
$9,890,000 | |
| Medtech Acquisition Corp |
Closed
999,999
|
$9,845,000 | |
| Senior Connect Acquisitn Cor |
Closed
1,000,000
|
$9,840,000 | |
| Revolution Healthcar Aq Corp |
Closed
1,000,000
|
$9,770,000 | |
| Pepgen Inc |
Closed
953,626
|
$9,470,000 | |
| Turmeric Acquisition Corp |
Closed
750,000
|
$7,448,000 | |
| Nkarta, Inc. |
Closed
600,000
|
$7,392,000 | |
| Ignyte Acquisition Corp |
Closed
725,000
|
$7,149,000 | |
| Apollo Endosurgery Inc |
Closed
1,750,000
|
$6,388,000 | |
| Xilio Therapeutics Inc |
Closed
2,078,692
|
$6,070,000 | |
| Outset Med Inc |
Closed
400,622
|
$5,953,000 | |
| Graybug Vision, Inc. |
Closed
5,281,713
|
$5,757,000 | |
| An2 Therapeutics Inc |
Closed
716,538
|
$5,553,000 | |
| Orion Acquisition Corp |
Closed
500,000
|
$4,900,000 | |
| Orchard Therapeutics plc |
Closed
6,949,416
|
$4,060,000 | |
| Oncorus, Inc. |
Closed
3,148,977
|
$3,968,000 | |
| Werewolf Therapeutics Inc |
Closed
958,125
|
$3,919,000 | |
| Quantum Si Inc |
Closed
1,400,000
|
$3,248,000 | |
| Kinnate Biopharma Inc. |
Closed
250,000
|
$3,153,000 | |
| Delcath Sys Inc |
Closed
500,000
|
$1,995,000 | |
| 89bio Inc |
Closed
506,100
|
$1,630,000 | |
| Medavail Holdings Inc |
Closed
836,626
|
$1,280,000 | |
| Rhythm Pharmaceuticals Inc. |
Closed
291,005
|
$1,208,000 | |
| Windtree Therapeutics, Inc. |
Closed
20,148
|
$8,000 | |
| Trisalus Life Sciences Inc |
Opened
1
|
$5,000 | 0.00% |
| No transactions found | |||
| Showing first 500 out of 119 holdings | |||
Hedge funds similar to Deerfield Management Company, L.P.. (series C)
- Sculptor Capital L.P.
- Davidson Kempner Partners
- Truepoint
- Parallel Advisors
- Gts Securities
- Aristotle Capital Boston
- Sumitomo Mitsui Financial Group, Inc
- Millburn Ridgefield Corp
- Mizuho Securities Usa
- Merit
- Systematic Financial Management L.P.
- Coldstream Capital Management Inc
- Comprehensive Management
- Channing Capital Management